<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181346</url>
  </required_header>
  <id_info>
    <org_study_id>IBCC 01</org_study_id>
    <nct_id>NCT04181346</nct_id>
  </id_info>
  <brief_title>Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting</brief_title>
  <official_title>Phase II Study of Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin
      can improve the complete control of nausea and vomiting (primary end point)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic
      chemotherapy.

      All patients will receive IV ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg
      before chemotherapy on day 1 and oral dexamethasone 4 mg, bd, on days 2 and 3.

      Patients will be randomly assigned to take pregabalin 75 mg or placebo, bd, from the night
      before chemotherapy to day 5.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic chemotherapy will be randomized for two arms: pregabalin and placebo.
All patients received will receive IV ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg, bd, on days 2 and 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving complete control of nausea and vomiting</measure>
    <time_frame>five days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, twice a day, from the night before chemotherapy to day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>antipsychotic</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to receive their first cycle of moderately to highly emetogenic
             chemotherapy;

          -  18 years or older;

          -  Eastern Cooperative Oncology Group &lt; 2

        Exclusion Criteria:

          -  Nausea or vomiting 24h before randomization

          -  aspartate aminotransferase / alanine aminotransferase above 3 times the upper limit

          -  Severe cognitive compromise;

          -  regular use of corticosteroids, opioid, benzodiazepines, tricyclic antidepressant, or
             cannabinoids within 30 days before randomization;

          -  brain metastasis;

          -  chronic alcoholism;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felipe Cruz, PhD</last_name>
    <phone>5511981388214</phone>
    <email>felipemcruz@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana Mauri, Dr</last_name>
    <phone>5511981366024</phone>
    <email>julianamauri@ibcc.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IBCC Oncologia</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>03102002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Cruz, PhD</last_name>
      <phone>5511981388214</phone>
      <email>felipemcruz@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Juliana Mauri, Dr</last_name>
      <phone>5511981388214</phone>
      <email>julianamauri@ibcc.org.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Felipe Melo Cruz</investigator_full_name>
    <investigator_title>PhD, Head of Medical Oncology Department</investigator_title>
  </responsible_party>
  <keyword>pregabalin</keyword>
  <keyword>nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

